|
TOPBP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.3797999998697E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.84691999999265E-05 |
| Normal-vs-Stage2 |
4.4904999999984E-05 |
| Normal-vs-Stage3 |
1.67839999998254E-06 |
| Normal-vs-Stage4 |
2.0314999999993E-05 |
| Stage1-vs-Stage2 |
2.805600E-01 |
| Stage1-vs-Stage3 |
1.849760E-01 |
| Stage1-vs-Stage4 |
3.536600E-01 |
| Stage2-vs-Stage3 |
9.330200E-01 |
| Stage2-vs-Stage4 |
8.685800E-01 |
| Stage3-vs-Stage4 |
9.238200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.16189999977668E-07 |
| Normal-vs-AfricanAmerican |
1.927870E-02 |
| Normal-vs-Asian |
1.875760E-03 |
| Caucasian-vs-AfricanAmerican |
5.071800E-01 |
| Caucasian-vs-Asian |
4.985800E-01 |
| AfricanAmerican-vs-Asian |
8.889800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.5038000001375E-07 |
| Normal-vs-Female |
2.10739999995102E-06 |
| Male-vs-Female |
2.672400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.785850E-04 |
| Normal-vs-Age(41-60Yrs) |
2.34579999980333E-07 |
| Normal-vs-Age(61-80Yrs) |
1.518569999992E-05 |
| Normal-vs-Age(81-100Yrs) |
4.657100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.247500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.430000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.420600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.198400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.436400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.511600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.383600E-01 |
| Classical-VS-Follicular |
2.122000E-03 |
| Classical-VS-Other |
1.932960E-01 |
| Classical-VS-Normal |
4.08720000000251E-05 |
| Tall-VS-Follicular |
1.641420E-01 |
| Tall-VS-Other |
3.348400E-01 |
| Tall-VS-Normal |
5.002600E-03 |
| Follicular-VS-Other |
8.274400E-01 |
| Follicular-VS-Normal |
2.60199999990718E-07 |
| Other-VS-Normal |
9.997300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.93560000436722E-08 |
| Normal-vs-N1 |
9.94479999999465E-05 |
| N0-vs-N1 |
8.098200E-01 |
|
|
